Fibrolamellar Carcinoma: 2012 Update
Fibrolamellar carcinomas are a unique type of primary liver cancer. They occur most commonly in children and young adults. Their etiology remains a mystery, as they are not associated with chronic liver disease. Fibrolamellar carcinomas are not indolent tumors, but have an overall better prognosis...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Scientifica |
| Online Access: | http://dx.doi.org/10.6064/2012/743790 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557123523837952 |
|---|---|
| author | Michael Torbenson |
| author_facet | Michael Torbenson |
| author_sort | Michael Torbenson |
| collection | DOAJ |
| description | Fibrolamellar carcinomas are a unique type of primary liver cancer. They occur most commonly in children and young adults. Their etiology remains a mystery, as they are not associated with chronic liver disease. Fibrolamellar carcinomas are not indolent tumors, but have an overall better prognosis than typical hepatocellular carcinomas, in part because of the younger age at presentation and the lack of cirrhosis. The most important prognostic feature is whether the tumor is resectable. Histologically, the tumor is made up of large cells that contain abundant mitochondria. The nuclei of the tumor cells have prominent nucleoli. The tumor cells induce the formation of extensive intratumoral fibrosis, which often grows in parallel, or lamellar bands. The tumor cells clearly show hepatocellular features but are also unique in showing both biliary and neuroendocrine differentiation. The uniqueness of fibrolamellar carcinoma extends to their molecular findings. While the genetic abnormalities that lead to fibrolamellar carcinomas are not yet known, studies have shown that they lack mutations in the genes most commonly mutated in typical hepatocellular carcinoma (TP53 and CTNNB1). In this paper, the clinical, pathological, and basic science literature on fibrolamellar carcinoma is comprehensively reviewed. Key areas of needed research are also discussed. |
| format | Article |
| id | doaj-art-b5849427bc964d418a9c33df5ba28c2a |
| institution | Kabale University |
| issn | 2090-908X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Scientifica |
| spelling | doaj-art-b5849427bc964d418a9c33df5ba28c2a2025-02-03T05:43:33ZengWileyScientifica2090-908X2012-01-01201210.6064/2012/743790743790Fibrolamellar Carcinoma: 2012 UpdateMichael Torbenson0Department of Pathology, The Johns Hopkins University School of Medicine, Room B314, 1503 E. Jefferson, Bond Street Building, Baltimore, MD 21231, USAFibrolamellar carcinomas are a unique type of primary liver cancer. They occur most commonly in children and young adults. Their etiology remains a mystery, as they are not associated with chronic liver disease. Fibrolamellar carcinomas are not indolent tumors, but have an overall better prognosis than typical hepatocellular carcinomas, in part because of the younger age at presentation and the lack of cirrhosis. The most important prognostic feature is whether the tumor is resectable. Histologically, the tumor is made up of large cells that contain abundant mitochondria. The nuclei of the tumor cells have prominent nucleoli. The tumor cells induce the formation of extensive intratumoral fibrosis, which often grows in parallel, or lamellar bands. The tumor cells clearly show hepatocellular features but are also unique in showing both biliary and neuroendocrine differentiation. The uniqueness of fibrolamellar carcinoma extends to their molecular findings. While the genetic abnormalities that lead to fibrolamellar carcinomas are not yet known, studies have shown that they lack mutations in the genes most commonly mutated in typical hepatocellular carcinoma (TP53 and CTNNB1). In this paper, the clinical, pathological, and basic science literature on fibrolamellar carcinoma is comprehensively reviewed. Key areas of needed research are also discussed.http://dx.doi.org/10.6064/2012/743790 |
| spellingShingle | Michael Torbenson Fibrolamellar Carcinoma: 2012 Update Scientifica |
| title | Fibrolamellar Carcinoma: 2012 Update |
| title_full | Fibrolamellar Carcinoma: 2012 Update |
| title_fullStr | Fibrolamellar Carcinoma: 2012 Update |
| title_full_unstemmed | Fibrolamellar Carcinoma: 2012 Update |
| title_short | Fibrolamellar Carcinoma: 2012 Update |
| title_sort | fibrolamellar carcinoma 2012 update |
| url | http://dx.doi.org/10.6064/2012/743790 |
| work_keys_str_mv | AT michaeltorbenson fibrolamellarcarcinoma2012update |